supplementary material – Page 224 – Communicable Diseases Research

Knowledge, attitude and perception of Pakistanis towards COVID-19; a large cross-sectional survey

Research Article

Published on 2021-01-052022-10-28
Journal: BMC Public Health [Category] COVID-19, MERS,

Charge-Transfer Resonance and Electromagnetic Enhancement Synergistically Enabling MXenes with Excellent SERS Sensitivity for SARS-CoV-2 S Protein Detection

Article

Published on 2021-01-052022-10-30
Journal: Nano-Micro Letters [Category] COVID-19,

Sedentary behaviour among general practitioners: a systematic review

Research Article

Published on 2021-01-042022-10-28
Journal: BMC Family Practice [Category] Coronavirus, MERS,

Alu retrotransposons and COVID-19 susceptibility and morbidity

Alu 레트로트랜스포존과 COVID-19 감수성 및 이환율

Review

Published on 2021-01-042022-09-10
Journal: Human Genomics [Category] MERS, 변종, 유전자 메커니즘,

Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)

입원한 COVID-19 환자의 중증 SARS-CoV-2 감염 예방을 위한 재조합 인간 C1 에스테라제 억제제(conestat alfa): 무작위, 병렬 그룹, 공개 라벨, 다중 센터에 대한 연구 프로토콜의 구조화된 요약 파일럿 시험(PROTECT-COVID-19)

Letter

Published on 2021-01-042022-09-10
Journal: Trials [Category] 임상,

[키워드] 24 hour 24 hours Activation activities acute lung injury addition adjusted Administered administration allergy Antibiotics anticipated anticoagulation arterial Arterial hypertension Basel Blinding BMI Brazil Breast Breast feeding breathing ambient air C-reactive protein C1 esterase inhibitor cardiovascular disease Caregivers changes in Chest Child-Pugh score chronic chronic pulmonary disease chronic renal disease cirrhosis class clinical Clinical improvement clinical trial comparator comparator Patients complement complement system completion conducted Conestat alfa Contact contact activation system contraindication control group Corticosteroids COVID-19 COVID-19 patient CT scan death defined discharge disease disease severity dissemination drug Duration Efficacy and safety element eligibility enrolment evidence of experimental arm family members FIVE followed by history hospital Hospitalization hospitalized patient hypertension ICU IL-6 inhibitor IL-6R improvement Incapacity include inclusion criteria individual Infection inflammatory cascade inflammatory cascades inflammatory proteins inhibitor Interactive Web Response System interim analysis Intravenous injection invasive invasive or non-invasive ventilation investigator-initiated investigators kallikrein kinin system laboratory parameter Liver cirrhosis Local Lung injury mechanical ventilation non-invasive ventilation not blinded number obesity objective Open-label open-label trial Ordinal Scale outcome outcome assessor outcome assessors oxygen oxygen saturation pandemic PaO parallel-group participant Participants Participation Patient performed Pregnancy primary endpoint progression proportion protocol pulmonary disease pulmonary involvement randomised randomization Randomized randomized trial receive recombinant recruited recruitment Registered Remdesivir renal renal disease required risk factor Sample size SARS-COV-2 infection SARS-CoV-2 pandemic scale screened secondary Secondary outcomes severe COVID-19 severe SARS-CoV-2 Standard of care status Study protocol subject supplemental oxygen supplementary material suspicion Switzerland Symptom the SARS-CoV-2 the WHO their family members Tocilizumab Treatment treatment arm Trial Two interim analyses Two interim analysis virological clearance website WHO WHO ordinal scale with COVID-19 X-ray
[DOI] 10.1186/s13063-020-04976-x PMC 바로가기 [Article Type] Letter

COVID-19-related medical research: a meta-research and critical appraisal

Research Article

Published on 2021-01-042022-10-28
Journal: BMC Medical Research Methodology [Category] COVID-19, Fulltext, MERS,

The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial

경증 및 중등도 COVID-19 환자에서 이버멕틴의 효능 및 안전성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-042022-09-10
Journal: Trials [Category] 임상, 치료제,

[키워드] 1:1 ACE inhibitor ACE inhibitors acute respiratory syndrome Adverse drug reaction Adverse drug reactions AIDS allergy anticipated Anticoagulant Anticoagulants Asthma Bandar Abbas Blinding Breastfeeding Captopril chest X-ray clinical clinical symptom Clinical symptoms clinical trial clinical trials company Computed tomography Confirmed Control control group control groups Controlled trial COVID-19 COVID-19 symptom criteria Critical CXR Department discharge Diseases dissemination dose Drug allergy education Efficacy and safety element evaluate exclusion criteria FIVE France group groups history Hospital stay Hospitalization Hospitalization Mechanical ventilation hydroxychloroquine sulfate ICU admission incidence include inclusion criteria India Infection Informed consent Inpatients Interferon beta-1a intervention group Iran Ivermectin Kidney disease liver loiasis Lopinavir Lopinavir/ritonavir mechanical ventilation Mild mild COVID-19 symptom mild COVID-19 symptoms mild pneumonia Ministry of Health moderate Moderate COVID-19 moderately severe COVID-19 MSD number objective Open-label Other outcome Outpatient outpatients parallel-group participant Patient patients patients with moderate PCR pharmaceutical Pharmaceutical Company Phase 3 Pneumonia Pregnancy Primary outcome Primary outcomes protocol random randomization Randomized Randomized controlled trial receive regimen Registered registration date registration number registry respiratory Ritonavir routine care Sample size secondary outcome selected Seven Severe acute respiratory syndrome single dose single-center standard treatment status Study protocol subsequent supplementary material table the patient Treatment treatment group Trial registration twice a day two group two groups underlying diseases Version Warfarin website weight
[DOI] 10.1186/s13063-020-04988-7 PMC 바로가기 [Article Type] Letter

Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: A structured summary of a study protocol for an open-label randomized clinical trial

비인두에서 COVID-19에 대한 포비돈 요오드의 바이러스 살균 효과: 공개 라벨 무작위 임상 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-042022-09-10
Journal: Trials [Category] 임상,

[키워드] 6 hour 6 hours acute renal failure adverse effect adverse effects adverse event adverse events anticipated Arm-1 ARMS assigned baseline being randomized Blinding both groups chronic renal failure clinical trial college comparator Concentration conducted confirmed case COVID-19 COVID-19 case COVID-19 virus creatinine criteria Data analysis diagnosed diet disease dissemination distilled water DMC Efficacy element eligibility assessment estimated glomerular filtration rate evaluate exclusion filtration rate Final glomerular filtration rate groups Identifier in both groups include Inclusion inclusion criteria independent Informed consent Intervention intervention arm intervention arms intervention group invasive involved Iodine KDIGO lactating masking Microsoft Excel Modification nasal Nasal Irrigation Nasal spray nasopharynx Noninvasive ventilation number objective Occurrence Open-label Other outcome parallel-group participant Patient performed Placebo positive Povidone Iodine pregnant women Primary outcome proportion protocol random number generation randomization Randomized randomized clinical trial RCT receive recruited Registered renal renal disease renal failure required routine care Sample size screened sealed secondary outcome sensitivity Seven single-center Stage statistician status Study protocol supplementary material Symptom Thyroid thyroid disease Trial trial protocol Trial registration Version virucidal virus website
[DOI] 10.1186/s13063-020-04963-2 PMC 바로가기 [Article Type] Letter

Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial

중등도에서 중증의 COVID-19(NACOVID) 치료를 위한 nitazoxanide + atazanavir/ritonavir의 효능 및 안전성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Comparative Study

Published on 2021-01-042022-09-10
Journal: Trials [Category] 신약개발, 임상, 치료제,

[키워드] 1:1 24 hour 24 hours achievement addition Administered African age allocation anticipated antiretroviral drugs antiviral activity approval Atazanavir atazanavir/ritonavir Blinding Care clinical Clinical improvement Clinical management Comorbidities confirmation Control control group COVID-19 COVID-19 diagnosis COVID-19 infection criteria defined determined by diagnosed Diagnosis discharge dissemination drug Drug administration drugs Efficacy and safety element eliminated enrolment exclusion criteria food Food and Drug Administration Gender group hospital hypersensitivity include inclusion criteria Infectious diseases information initiation of treatment Interaction intervention group Isolation lactating mechanical ventilation medication moderate moderate to severe multicentre Nasopharyngeal swab negativity Nigeria nitazoxanide number objective Ogun once daily Open-label open-label trial Ordinal Scale outcome measure Pan Pan African Clinical Trials Registry participant Patient PCR PCR test Phase 2 physician polymerase chain polymerase chain reaction positive pregnant Proportion of participant protocol quantified randomisation randomised randomised controlled trial receive receiving recruited REDCap Registered registry reported Ritonavir RT-PCR Saliva Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR SARS-CoV-2 polymerase chain reaction SARS-CoV-2 viral load secondary care sequence severe COVID-19 specialist Standard Standard of care state Stratification Study protocol supplementary material symptomatic Teaching Temporal the WHO time Treatment Trial Trial registration university Viral Viral load website working
[DOI] 10.1186/s13063-020-04987-8 PMC 바로가기 [Article Type] Comparative Study

Characteristic of Parkinson’s disease with severe COVID-19: a study of 10 cases from Wuhan

Observational Study

Published on 2021-01-032022-10-04
Journal: Journal of neural transmission (Vienna, Austria : [Category] MERS, 임상,